Michael J. Mack

TL;DR: The SAPIEN 3 THV may offer the opportunity to reduce the risk of annular rupture associated with more significant degrees of oversizing in borderline annular anatomy with acceptable rates of paravalvular aortic regurgitation being achieved at lower degrees of Oversizing.

TL;DR: Among the 975 patients in the NRCA-TA cohort, rates of major outcomes including death and stroke compared favorably with outcomes of PMA- TA and SAVR patients enrolled in the PARTNER trial, indicating a trend toward improved outcomes.

TL;DR: A joint position statement as discussed by the authors represents the combined efforts of four professional societies (Society of Thoracic Surgeons [STS], American Association for thoracic surgery [AATS], American College of Cardiology [ACC], and Society for Cardiovascular Angiography and Interventions [SCAI]), two government agencies (the U.S. Food and Drug Administration [FDA] and the Centers for Medicare and Medicaid Services [CMS]), and numerous industry representatives to assess the foreseeable directions of a class of emerging technologies being developed to enable the percutaneous treatment of cardiac

TL;DR: LV-MV ring size mismatch is associated with increased risk of MR recurrence, which may be helpful in guiding choice of ring size to prevent recurrent MR in patients undergoing MV repair and in identifying patients who may benefit from MV repair with additional subvalvular intervention or MV replacement rather than repair alone.

TL;DR: There is a higher risk of periprocedural stroke in patients undergoing CABG versus PCI; however, the risk converges over the first 4 years of follow-up.